Search Results | Blood | American Society of Hematology

1-20 of 92

2 3 4 5

Sort by

Sort Order Select

Journal Articles

MicroRNA-497/195 is tumor suppressive and cooperates with CDKN2A/B in pediatric acute lymphoblastic leukemia

Blood (2021) 138 (20): 1953–1965.

DOI: https://doi.org/10.1182/blood.2020007591

Published: 2021

Includes: Supplemental data

Journal Articles

Implication of ICOSLG on Relapse in Infant T(4;11) Acute Lymphoblastic Leukemia

Marius Külp, Anna Lena Siemund, Claus Meyer, Patrizia Larghero, Alissa Dietz, Julia Alten, Gunnar Cario, Aurélie Caye-Eude, Hélène Cavé, Michela Bardini, Paola De Lorenzo, Giovanni Cazzaniga, Laura Diehl, Halvard Bonig, Rolf Marschalek

Blood (2021) 138 (Supplement 1): 3481.

DOI: https://doi.org/10.1182/blood-2021-146181

Published: 2021

Journal Articles

Preclinical Evidence for the Efficacy of CD79b Immunotherapy in B Cell Precursor Acute Lymphoblastic Leukemia

Lennart Lenk, Dorothee Winterberg, Fotini Vogiatzi, Anna Laqua, Lea Spory, Ahmad Mayar, Christian Vokuhl, Julia Richter, Michela Carlet, Irmela Jeremias, Thomas Valerius, Martin Schrappe, Gunnar Cario, Hassan Jumaa, Elias Hobeika, Monika Brüggemann, Ameera Alsadeq, Denis Martin Schewe

Blood (2021) 138 (Supplement 1): 2388.

DOI: https://doi.org/10.1182/blood-2021-148429

Published: 2021

Journal Articles

IL7R Targeting Using OSE-127 Shows Robust Anti-Leukemic Activity in B-Cell Precursor Acute Lymphoblastic Leukemia Xenografts

Lennart Lenk, Irène Baccelli, Dorothee Winterberg, Frédérique Corallo, Fotini Vogiatzi, Lea Spory, Martin Schrappe, Gunnar Cario, Anna Laqua, Monika Brüggemann, Nicolas Poirier, Denis Martin Schewe

Blood (2021) 138 (Supplement 1): 1313.

DOI: https://doi.org/10.1182/blood-2021-150323

Published: 2021

Journal Articles

TP53 and KRAS Variants at Initial Diagnosis Identify an Ultra-High Risk Group of Pediatric T-Lymphoblastic Leukemia (T-ALL)

Tamara Kempter, Joachim B. Kunz, Paulina Richter-Pechanska, Katarzyna Tomska, Tobias Rausch, Busra Erarslan-Uysal, Cornelia Eckert, Martin Zimmermann, Martin Stanulla, Martin Schrappe, Gunnar Cario, Gabriele Escherich, Renate Kirschner-Schwabe, Martina U. Muckenthaler, Jan O. Korbel, Andreas E. Kulozik

Blood (2021) 138 (Supplement 1): 1315.

DOI: https://doi.org/10.1182/blood-2021-148420

Published: 2021

Journal Articles

Remission, treatment failure, and relapse in pediatric ALL: An international consensus of the Ponte-di-Legno Consortium

Blood blood.2021012328.

DOI: https://doi.org/10.1182/blood.2021012328

Published: 2021

Includes: Supplemental data

Journal Articles

MondoA Drives B-ALL Malignancy through Enhanced Adaptation to Metabolic Stress

Blood blood.2020007932.

DOI: https://doi.org/10.1182/blood.2020007932

Published: 2021

Includes: Supplemental data

Journal Articles

Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia Harboring Heterogeneous Genomic Profiles Respond to Venetoclax in Combination with Chemotherapy

Andrew E. Place, MDPhD, Seth E. Karol, MD, Christopher J. Forlenza, MD, Marion Gambart, MD, Todd M. Cooper, DO, Christopher Fraser, MBBS, Gunnar Cario, MD PhD, Maureen M O'Brien, MD, Nicolas U. Gerber, MD, Phillip Barnette, MD, Dirk Reinhardt, MDPhD, Giridharan Ramsingh, MD, Bo Tong, PhD, Kristina Unnebrink, PhD, Deeksha Vishwamitra, PhD, Fengjiao Dunbar, PhD, Betty A. Prine, BS, Tammy L. Palenski, PhD, Mignon L. Loh, MD

Blood (2020) 136 (Supplement 1): 37–38.

DOI: https://doi.org/10.1182/blood-2020-137376

Published: 2020

Journal Articles

Co-Targeting of CD38 and CD47 in T Cell Acute Lymphoblastic Leukemia

Fotini Vogiatzi, PhD, Kristina Müller, Dorothee Winterberg, Thies Rösner, PhD, Lennart Lenk, PhD, Gunnar Cario, MD PhD, Martin Schrappe, MDPhD, Andreas E. Kulozik, MD PhD, Beat Bornhauser, Jean-Pierre Bourquin, MD PhD, Thomas Valerius, MD, Matthias Peipp, PhD, Christian Kellner, PhD, Denis Martin Schewe, MD

Blood (2020) 136 (Supplement 1): 39–40.

DOI: https://doi.org/10.1182/blood-2020-140270

Published: 2020

Journal Articles

In Vitro Drug Response Profiling in BCP- and T-ALL Primary Samples Adds a Robust Functional Layer Enabling Optimized Guidance of Individualized Therapy in Relapsed and Refractory Pediatric Acute Leukemia Patients

Blood (2020) 136 (Supplement 1): 15–16.

DOI: https://doi.org/10.1182/blood-2020-142314

Published: 2020

Journal Articles

Poor Prognosis in Children with ABL -Class Fusion Positive B-Cell Acute Lymphoblastic Leukemia Treated According to AIEOP-BFM Protocols

Blood (2019) 134 (Supplement_1): 1351.

DOI: https://doi.org/10.1182/blood-2019-126523

Published: 2019

Journal Articles

Urine Proteomic Analysis Reveals Disease-Specific Patterns in Pediatric Patients with Classical Hodgkin's Disease(HD). an Addon Study to the Euronet-PHL-C2 Trial

Blood (2019) 134 (Supplement_1): 2804.

DOI: https://doi.org/10.1182/blood-2019-125611

Published: 2019

Journal Articles

Safety, Efficacy, and PK of the BCL2 Inhibitor Venetoclax in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Phase 1 Study

Seth E Karol, MD, Todd M Cooper, DO, Henrique Bittencourt, Lia Gore, MD, Maureen M O'Brien, MD, Christopher Fraser, MD, Marion Gambart, MD, Gunnar Cario, MD PhD, Christian Michel Zwaan, MD PhD, Jean-Pierre Bourquin, MD PhD, Mignon L. Loh, MD, Hubert Caron, MD PhD, Betty Prine, Ahmed Hamed Salem, PhD FCP, Kristina Unnebrink, Bo Tong, PhD, Tammy Palenski, PhD, Andrew E. Place, MD PhD

Blood (2019) 134 (Supplement_1): 2649.

DOI: https://doi.org/10.1182/blood-2019-129805

Published: 2019

Journal Articles

Incidence of Hypersensitivity Reactions (HSR) Reactions (HSR) to Peg-Asparaginase (PEG-ASP) in 6136 Patients Treated in the AIEOP-BFM ALL 2009 Study Protocol

Carmelo Rizzari, Anja Moericke, MD, Valentino Conter, MD, Maria Grazia Valsecchi, PhD, Martin Zimmermann, PhD, Daniela Silvestri, Georg Mann, MD, Felix Niggli, MD, Luciano Dalla-Pozza, MBBS FRACP, Jan Stary, Prof., MD PhD, Sarah Elitzur, MD, Gunnar Cario, MD, Franco Locatelli, MD, Joachim Boos, MD, Massimo Zucchetti, PharmD, Andrea Biondi, MD, Martin Schrappe, MD PhD

Blood (2019) 134 (Supplement_1): 2589.

DOI: https://doi.org/10.1182/blood-2019-123448

Published: 2019

Journal Articles

Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia

Fotini Vogiatzi, Dorothee Winterberg, Lennart Lenk, Swantje Buchmann, Gunnar Cario, Martin Schrappe, Matthias Peipp, Paulina Richter-Pechanska, Andreas E. Kulozik, Jana Lentes, Anke K. Bergmann, Thomas Valerius, Fabian-Simon Frielitz, Christian Kellner, Denis M. Schewe

Blood (2019) 134 (8): 713–716.

DOI: https://doi.org/10.1182/blood.2019000904

Published: 2019

Includes: Supplemental data

Journal Articles

CD79a Is Associated with Central Nervous System Infiltration of Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia

Lennart Lenk, PhD MSc, Fotini Vogiatzi, PhD, Michela Carlet, PhD, Christian Vokuhl, MD, Gunnar Cario, MD, Martin Schrappe, MD PhD, Irmela Jeremias, MD PhD, Stephan Fuhrmann, MD, Elias Hobeika, PhD, Hassan Jumaa, Prof. Dr., Ameera Alsadeq, PhD, Denis Martin Schewe, MD

Blood (2018) 132 (Supplement 1): 386.

DOI: https://doi.org/10.1182/blood-2018-99-114595

Published: 2018

Journal Articles

Pediatric T-ALLs Developing into a Type 2 Relapse Originate from Cells That Carry the Potential of Variable Maturation into Subclones with Distinct Chromatin Landscapes

Blood (2018) 132 (Supplement 1): 1545.

DOI: https://doi.org/10.1182/blood-2018-99-118255

Published: 2018

Journal Articles

Venetoclax Enhances the Efficacy of Therapeutic Antibodies in B-Cell Malignancies

Fotini Vogiatzi, PhD, Julia Heymann, Thies Rösner, PhD, Lennart Lenk, PhD MSc, Gunnar Cario, MD, Martin Schrappe, MD PhD, Beat Bornhauser, PhD, Jean-Pierre Bourquin, MD PhD, Simon Bomken, MD, Thomas Valerius, MD, Matthias Peipp, PhD, Christian Kellner, PhD, Denis Martin Schewe, MD

Blood (2018) 132 (Supplement 1): 4177.

DOI: https://doi.org/10.1182/blood-2018-99-114677

Published: 2018

Journal Articles

Longitudinal Multilevel Omic Analysis of Pediatric T-ALL Reveals Distinct Mechanisms for Disease Progression in Type 1 and in Type 2 Relapses

Blood (2018) 132 (Supplement 1): 2826.

DOI: https://doi.org/10.1182/blood-2018-99-117978

Published: 2018

Journal Articles

Methotrexate-Associated Toxicity in Children with Down Syndrome and Acute Lymphoblastic Leukemia during Consolidation Therapy with High Dose Methotrexate According to ALL-BFM Treatment Regimen

Mirko Kroll, Kirsten Bleckmann, MD, Anja Möricke, MD, Denis Martin Schewe, MD, Martin Stanulla, MD PhD, Martin Zimmermann, PhD, Martin Schrappe, MD PhD, Gunnar Cario, MD

Blood (2018) 132 (Supplement 1): 1378.

DOI: https://doi.org/10.1182/blood-2018-99-112114

Published: 2018

2 3 4 5

NARROW

MicroRNA-497/195 is tumor suppressive and cooperates with CDKN2A/B in pediatric acute lymphoblastic leukemia

Implication of ICOSLG on Relapse in Infant T(4;11) Acute Lymphoblastic Leukemia

Preclinical Evidence for the Efficacy of CD79b Immunotherapy in B Cell Precursor Acute Lymphoblastic Leukemia

IL7R Targeting Using OSE-127 Shows Robust Anti-Leukemic Activity in B-Cell Precursor Acute Lymphoblastic Leukemia Xenografts

TP53 and KRAS Variants at Initial Diagnosis Identify an Ultra-High Risk Group of Pediatric T-Lymphoblastic Leukemia (T-ALL)

Remission, treatment failure, and relapse in pediatric ALL: An international consensus of the Ponte-di-Legno Consortium

MondoA Drives B-ALL Malignancy through Enhanced Adaptation to Metabolic Stress

Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia Harboring Heterogeneous Genomic Profiles Respond to Venetoclax in Combination with Chemotherapy

Co-Targeting of CD38 and CD47 in T Cell Acute Lymphoblastic Leukemia

In Vitro Drug Response Profiling in BCP- and T-ALL Primary Samples Adds a Robust Functional Layer Enabling Optimized Guidance of Individualized Therapy in Relapsed and Refractory Pediatric Acute Leukemia Patients

Poor Prognosis in Children with ABL -Class Fusion Positive B-Cell Acute Lymphoblastic Leukemia Treated According to AIEOP-BFM Protocols

Urine Proteomic Analysis Reveals Disease-Specific Patterns in Pediatric Patients with Classical Hodgkin's Disease(HD). an Addon Study to the Euronet-PHL-C2 Trial

Safety, Efficacy, and PK of the BCL2 Inhibitor Venetoclax in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Phase 1 Study

Incidence of Hypersensitivity Reactions (HSR) Reactions (HSR) to Peg-Asparaginase (PEG-ASP) in 6136 Patients Treated in the AIEOP-BFM ALL 2009 Study Protocol

Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia

CD79a Is Associated with Central Nervous System Infiltration of Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia

Pediatric T-ALLs Developing into a Type 2 Relapse Originate from Cells That Carry the Potential of Variable Maturation into Subclones with Distinct Chromatin Landscapes

Venetoclax Enhances the Efficacy of Therapeutic Antibodies in B-Cell Malignancies

Longitudinal Multilevel Omic Analysis of Pediatric T-ALL Reveals Distinct Mechanisms for Disease Progression in Type 1 and in Type 2 Relapses

Methotrexate-Associated Toxicity in Children with Down Syndrome and Acute Lymphoblastic Leukemia during Consolidation Therapy with High Dose Methotrexate According to ALL-BFM Treatment Regimen

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only